Vempuluru Vijitha S, Tanna Vishakha, Luthra Anshika, Kaliki Swathi
The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute (V.S.V., V.T., A.L., and S.K.), Hyderabad, Telangana, India.
The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute (V.S.V., V.T., A.L., and S.K.), Hyderabad, Telangana, India.
Am J Ophthalmol. 2025 Jan;269:49-59. doi: 10.1016/j.ajo.2024.07.036. Epub 2024 Aug 3.
To analyze the outcomes of eyelid and periocular sebaceous gland carcinoma (SGC) based on prognostic stage of the 8th edition of American Joint Committee on Cancer (AJCC) classification.
Retrospective study METHODS: Study of 500 eyes with SGC RESULTS: Based on the 8th edition of AJCC classification, tumors belonged to Stage 0 (n=13, 3%), I (n=158, 32%), II (n=269, 54%), III (n=48, 9%), and IV (n=12, 2%). The 5-year Kaplan-Meier estimates of regional lymph node metastasis, systemic metastasis, and metastasis-related death were higher for stage II (12%, 11%, and 12%, respectively), III (69%, 25%, and 42%, respectively) and IV (70%, 100%, and 100%, respectively) compared to stage I (0%, 6%, and 6%, respectively). Cox proportional analysis revealed a greater hazard ratio (HR) for lymph node metastasis in stage II (HR, 3.498; 95% CI, 0.200 to 10.200; p<0.022), III (HR, 95% CI, 24.836; 8.733 to 70.631; p<0.001), and IV (HR, 53.731; 95% CI, 15.418 to 187.253; p<0.001), systemic metastasis in stage III (HR. 13.895; 95% CI, 3.871 to 49.874; p<0.001) and IV (HR, 81.465; 95% CI, 22.267 to 298.051; p<0.001) and for disease-related death in stage III (HR, 9.182; 95% CI, 2.743 to 30.728; p<0.001) and IV (HR, 85.237; 95% CI, 25.331 to 287.422; p<0.001), compared to stage I.
The prognostic staging of the 8th edition AJCC classification predicts the prognosis of patients with eyelid and periocular SGC, which worsens with the advancing stage. The high incidence of lymph node and systemic metastasis accounts for mortality in these patients.
基于美国癌症联合委员会(AJCC)第8版分类的预后分期,分析眼睑及眼周皮脂腺癌(SGC)的治疗结果。
回顾性研究
对500例患有SGC的眼睛进行研究
根据AJCC第8版分类,肿瘤属于0期(n = 13,3%)、I期(n = 158,32%)、II期(n = 269,54%)、III期(n = 48,9%)和IV期(n = 12,2%)。与I期(分别为0%、6%和6%)相比,II期(分别为12%、11%和12%)、III期(分别为69%、25%和42%)和IV期(分别为70%、100%和100%)的区域淋巴结转移、全身转移及转移相关死亡的5年Kaplan-Meier估计值更高。Cox比例分析显示,与I期相比,II期(风险比[HR],3.498;95%置信区间[CI],0.200至10.200;p<0.022)、III期(HR,95% CI,24.836;8.733至70.631;p<0.001)和IV期(HR,53.731;95% CI,15.418至187.253;p<0.001)发生淋巴结转移的HR更高,III期(HR,13.895;95% CI,3.871至49.874;p<0.001)和IV期(HR,81.465;95% CI,22.267至298.051;p<0.001)发生全身转移的HR更高,III期(HR,9.182;95% CI,2.743至30.728;p<0.001)和IV期(HR,85.237;95% CI,25.331至287.422;p<0.001)因疾病相关死亡的HR更高。
AJCC第8版分类的预后分期可预测眼睑及眼周SGC患者的预后,且随着分期进展预后恶化。淋巴结和全身转移的高发生率是这些患者死亡的原因。